C Arden Pope1, Aruni Bhatnagar2, James P McCracken2, Wesley Abplanalp2, Daniel J Conklin2, Timothy O'Toole2. 1. From the Department of Economics, Brigham Young University, Provo, UT (C.A.P.); and Diabetes and Obesity Center, Division of Cardiovascular Medicine, Department of Medicine, University of Louisville, KY (A.B., J.P.M., W.A., D.J.C., T.O.). cap3@byu.edu. 2. From the Department of Economics, Brigham Young University, Provo, UT (C.A.P.); and Diabetes and Obesity Center, Division of Cardiovascular Medicine, Department of Medicine, University of Louisville, KY (A.B., J.P.M., W.A., D.J.C., T.O.).
Abstract
RATIONALE: Epidemiological evidence indicates that exposures to fine particulate matter air pollution (PM2.5) contribute to global burden of disease, primarily as a result of increased risk of cardiovascular morbidity and mortality. However, mechanisms by which PM2.5 exposure induces cardiovascular injury remain unclear. PM2.5-induced endothelial dysfunction and systemic inflammation have been implicated, but direct evidence is lacking. OBJECTIVE: To examine whether acute exposure to PM2.5 is associated with endothelial injury and systemic inflammation. METHODS AND RESULTS: Blood was collected from healthy, nonsmoking, young adults during 3 study periods that included episodes of elevated PM2.5 levels. Microparticles and immune cells in blood were measured by flow cytometry, and plasma cytokine/growth factors were measured using multiplexing laser beads. PM2.5 exposure was associated with the elevated levels of endothelial microparticles (annexin V+/CD41-/CD31+), including subtypes expressing arterial-, venous-, and lung-specific markers, but not microparticles expressing CD62+. These changes were accompanied by suppressed circulating levels of proangiogenic growth factors (EGF [epidermal growth factor], sCD40L [soluble CD40 ligand], PDGF [platelet-derived growth factor], RANTES [regulated on activation, normal T-cell-expressed and secreted], GROα [growth-regulated protein α], and VEGF [vascular endothelial growth factor]), and an increase in the levels of antiangiogenic (TNFα [tumor necrosis factor α], IP-10 [interferon γ-induced protein 10]), and proinflammatory cytokines (MCP-1 [monocyte chemoattractant protein 1], MIP-1α/β [macrophage inflammatory protein 1α/β], IL-6 [interleukin 6], and IL-1β [interleukin 1β]), and markers of endothelial adhesion (sICAM-1 [soluble intercellular adhesion molecule 1] and sVCAM-1 [soluble vascular cellular adhesion molecule 1]). PM2.5 exposure was also associated with an inflammatory response characterized by elevated levels of circulating CD14+, CD16+, CD4+, and CD8+, but not CD19+ cells. CONCLUSIONS: Episodic PM2.5 exposures are associated with increased endothelial cell apoptosis, an antiangiogenic plasma profile, and elevated levels of circulating monocytes and T, but not B, lymphocytes. These changes could contribute to the pathogenic sequelae of atherogenesis and acute coronary events.
RATIONALE: Epidemiological evidence indicates that exposures to fine particulate matter air pollution (PM2.5) contribute to global burden of disease, primarily as a result of increased risk of cardiovascular morbidity and mortality. However, mechanisms by which PM2.5 exposure induces cardiovascular injury remain unclear. PM2.5-induced endothelial dysfunction and systemic inflammation have been implicated, but direct evidence is lacking. OBJECTIVE: To examine whether acute exposure to PM2.5 is associated with endothelial injury and systemic inflammation. METHODS AND RESULTS: Blood was collected from healthy, nonsmoking, young adults during 3 study periods that included episodes of elevated PM2.5 levels. Microparticles and immune cells in blood were measured by flow cytometry, and plasma cytokine/growth factors were measured using multiplexing laser beads. PM2.5 exposure was associated with the elevated levels of endothelial microparticles (annexin V+/CD41-/CD31+), including subtypes expressing arterial-, venous-, and lung-specific markers, but not microparticles expressing CD62+. These changes were accompanied by suppressed circulating levels of proangiogenic growth factors (EGF [epidermal growth factor], sCD40L [soluble CD40 ligand], PDGF [platelet-derived growth factor], RANTES [regulated on activation, normal T-cell-expressed and secreted], GROα [growth-regulated protein α], and VEGF [vascular endothelial growth factor]), and an increase in the levels of antiangiogenic (TNFα [tumor necrosis factor α], IP-10 [interferon γ-induced protein 10]), and proinflammatory cytokines (MCP-1 [monocyte chemoattractant protein 1], MIP-1α/β [macrophage inflammatory protein 1α/β], IL-6 [interleukin 6], and IL-1β [interleukin 1β]), and markers of endothelial adhesion (sICAM-1 [soluble intercellular adhesion molecule 1] and sVCAM-1 [soluble vascular cellular adhesion molecule 1]). PM2.5 exposure was also associated with an inflammatory response characterized by elevated levels of circulating CD14+, CD16+, CD4+, and CD8+, but not CD19+ cells. CONCLUSIONS:EpisodicPM2.5 exposures are associated with increased endothelial cell apoptosis, an antiangiogenic plasma profile, and elevated levels of circulating monocytes and T, but not B, lymphocytes. These changes could contribute to the pathogenic sequelae of atherogenesis and acute coronary events.
Authors: Joel D Kaufman; Sara D Adar; R Graham Barr; Matthew Budoff; Gregory L Burke; Cynthia L Curl; Martha L Daviglus; Ana V Diez Roux; Amanda J Gassett; David R Jacobs; Richard Kronmal; Timothy V Larson; Ana Navas-Acien; Casey Olives; Paul D Sampson; Lianne Sheppard; David S Siscovick; James H Stein; Adam A Szpiro; Karol E Watson Journal: Lancet Date: 2016-05-24 Impact factor: 79.321
Authors: Andreas Edsfeldt; Helena Grufman; Giuseppe Asciutto; Mihaela Nitulescu; Ana Persson; Marie Nilsson; Jan Nilsson; Isabel Gonçalves Journal: Atherosclerosis Date: 2015-06-03 Impact factor: 5.162
Authors: C Arden Pope; Richard T Burnett; Michael J Thun; Eugenia E Calle; Daniel Krewski; Kazuhiko Ito; George D Thurston Journal: JAMA Date: 2002-03-06 Impact factor: 56.272
Authors: Maresa Caunt; Liang Hu; Thomas Tang; Peter C Brooks; Sherif Ibrahim; Simon Karpatkin Journal: Cancer Res Date: 2006-04-15 Impact factor: 12.701
Authors: C Arden Pope; Richard T Burnett; George D Thurston; Michael J Thun; Eugenia E Calle; Daniel Krewski; John J Godleski Journal: Circulation Date: 2003-12-15 Impact factor: 29.690
Authors: Jada L Brooks; Diane C Berry; Emily G Currin; Alasia Ledford; George J Knafl; Barbara L Fredrickson; Linda S Beeber; David B Peden; Giselle M Corbie-Smith Journal: Res Nurs Health Date: 2019-03-28 Impact factor: 2.228
Authors: John P Reilly; Zhiguo Zhao; Michael G S Shashaty; Tatsuki Koyama; Jason D Christie; Paul N Lanken; Chunxue Wang; John R Balmes; Michael A Matthay; Carolyn S Calfee; Lorraine B Ware Journal: Am J Respir Crit Care Med Date: 2019-01-01 Impact factor: 21.405
Authors: Dag G Ellingsen; Maxim Chashchin; Ingebjørg Seljeflot; Balazs Berlinger; Valery Chashchin; Leo Stockfelt; Yngvar Thomassen Journal: Int Arch Occup Environ Health Date: 2019-05-21 Impact factor: 3.015
Authors: Natalie C DuPré; Jaime E Hart; Michelle D Holmes; Elizabeth M Poole; Peter James; Peter Kraft; Francine Laden; Rulla M Tamimi Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-01-15 Impact factor: 4.254
Authors: Daniel J Conklin; Suzaynn Schick; Michael J Blaha; Alex Carll; Andrew DeFilippis; Peter Ganz; Michael E Hall; Naomi Hamburg; Tim O'Toole; Lindsay Reynolds; Sanjay Srivastava; Aruni Bhatnagar Journal: Am J Physiol Heart Circ Physiol Date: 2019-02-01 Impact factor: 4.733
Authors: Benjamin C Nephew; Alexandra Nemeth; Neelakshi Hudda; Gillian Beamer; Phyllis Mann; Jocelyn Petitto; Ryan Cali; Marcelo Febo; Praveen Kulkarni; Guillaume Poirier; Jean King; John L Durant; Doug Brugge Journal: Environ Res Date: 2020-02-17 Impact factor: 6.498